Trials / Completed
CompletedNCT04534270
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Efficacy and Safety of Dapagliflozin in Non-diabetic Children With Proteinuria
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Children's Hospital of Fudan University · Academic / Other
- Sex
- All
- Age
- 6 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks |
Timeline
- Start date
- 2020-07-06
- Primary completion
- 2021-12-30
- Completion
- 2022-03-30
- First posted
- 2020-09-01
- Last updated
- 2022-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04534270. Inclusion in this directory is not an endorsement.